Loading...
XNYSMDT
Market cap103bUSD
Dec 20, Last price  
81.03USD
1D
1.30%
1Q
-9.30%
Jan 2017
13.76%
Name

Medtronic PLC

Chart & Performance

D1W1MN
XNYS:MDT chart
P/E
28.27
P/S
3.21
EPS
2.87
Div Yield, %
3.53%
Shrs. gr., 5y
-0.41%
Rev. gr., 5y
1.16%
Revenues
32.36b
+3.64%
10,054,600,00011,292,000,00012,299,000,00013,515,000,00014,599,000,00015,817,000,00015,933,000,00016,184,000,00016,590,000,00017,005,000,00020,261,000,00028,833,000,00029,710,000,00029,953,000,00030,557,000,00028,913,000,00030,117,000,00031,686,000,00031,227,000,00032,364,000,000
Net income
3.68b
-2.18%
1,803,900,0002,546,700,0002,802,000,0002,231,000,0002,169,000,0003,099,000,0003,096,000,0003,617,000,0003,467,000,0003,065,000,0002,675,000,0003,538,000,0004,028,000,0003,104,000,0004,631,000,0004,789,000,0003,606,000,0005,039,000,0003,758,000,0003,676,000,000
CFO
6.79b
+12.39%
2,819,400,0002,207,400,0002,979,000,0003,489,000,0003,878,000,0004,131,000,0003,741,000,0004,381,000,0004,883,000,0004,959,000,0004,902,000,0005,218,000,0006,880,000,0004,684,000,0007,007,000,0007,234,000,0006,240,000,0007,346,000,0006,039,000,0006,787,000,000
Dividend
Sep 27, 20240.7 USD/sh
Earnings
Feb 18, 2025

Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
URL
https://www.medtronic.com/
IPO date
Nov 21, 1977
Employees
95,000
Domiciled in
IE
Incorporated in
IE

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑042023‑042022‑042021‑042020‑042019‑042018‑042017‑042016‑042015‑04
Income
Revenues
32,364,000
3.64%
31,227,000
-1.45%
31,686,000
5.21%
Cost of revenue
13,951,000
13,415,000
12,891,000
Unusual Expense (Income)
NOPBT
18,413,000
17,812,000
18,795,000
NOPBT Margin
56.89%
57.04%
59.32%
Operating Taxes
1,133,000
1,580,000
456,000
Tax Rate
6.15%
8.87%
2.43%
NOPAT
17,280,000
16,232,000
18,339,000
Net income
3,676,000
-2.18%
3,758,000
-25.42%
5,039,000
39.74%
Dividends
(3,666,000)
(3,616,000)
(3,383,000)
Dividend yield
3.46%
2.98%
2.40%
Proceeds from repurchase of equity
(1,854,000)
(337,000)
(2,115,000)
BB yield
1.75%
0.28%
1.50%
Debt
Debt current
1,275,000
200,000
3,742,000
Long-term debt
25,667,000
24,408,000
20,434,000
Deferred revenue
91,000
94,000
Other long-term liabilities
3,485,000
5,180,000
4,515,000
Net debt
17,321,000
15,009,000
12,554,000
Cash flow
Cash from operating activities
6,787,000
6,039,000
7,346,000
CAPEX
(1,587,000)
(1,459,000)
(1,368,000)
Cash from investing activities
(2,366,000)
(3,493,000)
(1,659,000)
Cash from financing activities
(4,450,000)
(4,960,000)
(5,336,000)
FCF
15,351,000
14,519,000
17,546,000
Balance
Cash
8,005,000
7,959,000
10,573,000
Long term investments
1,616,000
1,640,000
1,049,000
Excess cash
8,002,800
8,037,650
10,037,700
Stockholders' equity
27,291,000
27,075,000
28,156,000
Invested Capital
71,949,200
73,037,350
70,703,300
ROIC
23.84%
22.59%
25.51%
ROCE
22.88%
21.78%
23.03%
EV
Common stock shares outstanding
1,330,200
1,332,800
1,351,400
Price
79.74
-12.33%
90.95
-12.85%
104.36
-20.29%
Market cap
106,070,148
-12.50%
121,218,160
-14.05%
141,032,104
-20.44%
EV
123,597,148
136,409,160
153,757,104
EBITDA
21,060,000
20,509,000
21,502,000
EV/EBITDA
5.87
6.65
7.15
Interest
719,000
636,000
553,000
Interest/NOPBT
3.90%
3.57%
2.94%